Abstract
A blog that publishes updates and open access scientific papers about allergy, asthma and immunology. Editor: Juan Carlos Ivancevich, MD. Specialist in Allergy & Immunology
August 4, 2015
What pulmonologists think about the asthma–COPD overlap syndrome
Authors Miravitlles M, Alcázar B, Alvarez FJ, Bazús T, Calle M, Casanova C, Cisneros C, de-Torres JP, Entrenas LM, Esteban C, García-Sidro P, Cosio BG, Huerta A, Iriberri M, Izquierdo JL, López-Viña A, López-Campos JL, Martínez-Moragón E, Pérez de Llano L, Perpiñá M, Ros JA, Serrano J, Soler-Cataluña JJ, Torrego A, Urrutia I, Plaza V
Published Date July 2015 Volume 2015:10(1) Pages 1321—1330
Received 15 May 2015, Accepted 23 June 2015, Published 15 July 2015
Peer reviewers approved by Dr Hsiao-Chi Chuang
Approved for publication by Dr Richard Russell
Background: Some patients with COPD may share characteristics of asthma; this is the so-called asthma–COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population.
Materials and methods: We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS.
Clinical contraindications to allergen immunotherapy: an EAACI position paper
- C. Pitsios1,*,
- P. Demoly2,3,
- M. B. Bilò4,
- R. Gerth van Wijk5,
- O. Pfaar6,7,
- G. J. Sturm8,
- P. Rodriguez del Rio9,
- M. Tsoumani10,
- R. Gawlik11,
- G. Paraskevopoulos12,
- F. Ruëff13,
- E. Valovirta14,
- N. G. Papadopoulos15,16and
- M. A. Calderón17
Abstract
Clinical indications for allergen immunotherapy (AIT) in respiratory and Hymenoptera venom allergy are well established; however, clinical contraindications to AIT are not always well documented. There are some discrepancies when classifying clinical contraindications for different forms of AIT as ‘absolute’ or ‘relative’. EAACI Task Force on ‘Contraindications to AIT’ was created to evaluate and review current literature on clinical contraindications, and to update recommendations for both sublingual and subcutaneous AIT for respiratory and venom immunotherapy.
August 3, 2015
Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial
Research
Ludger Klimek1*, Claus Bachert2, Karl-Friedrich Lukat3, Oliver Pfaar5, Hanns Meyer4 and Annemie Narkus4
Abstract (provisional)
Background Pollen extracts and chemically modified allergoids are used successfully in allergen immunotherapy (AIT). Recombinant extracts offer potential advantages with respect to pharmaceutical quality, standardization and dosing. A hypoallergenic recombinant folding variant of the major birch pollen allergen (rBet v 1-FV) was compared with an established native birch preparation.
Protocadherin-1 is a glucocorticoid-responsive critical regulator of airway epithelial barrier function
Research article
Yutaka Kozu1, Yasuhiro Gon1*, Shuichiro Maruoka1, Kuroda Kazumichi2, Akiko Sekiyama1, Hiroyuki Kishi3, Yasuyuki Nomura3, Minoru Ikeda3 and Shu Hashimoto1
Impaired epithelial barrier function renders the airway vulnerable to environmental triggers associated with the pathogenesis of bronchial asthma. We investigated the influence of protocadherin-1 (PCDH1), a susceptibility gene for bronchial hyperresponsiveness, on airway epithelial barrier function.
We applied transepithelial electric resistance and dextran permeability testing to evaluate the barrier function of cultured airway epithelial cells. We studied PCDH1 function by siRNA-mediated knockdown and analyzed nasal or bronchial tissues from 16 patients with chronic rhinosinusitis (CRS) and nine patients with bronchial asthma for PCDH1 expression.
Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants
Position article and guidelines
David M. Fleischer1, Scott Sicherer2, Matthew Greenhawt3, Dianne Campbell4, Edmond S. Chan5*, Antonella Muraro6,Susanne Halken6, Yitzhak Katz7, Motohiro Ebisawa8, Lawrence Eichenfield9, Hugh Sampson10, For the Leap Study Team and Secondary Contributors
Abstract (provisional)
The purpose of this brief communication is to highlight emerging evidence to existing guidelines regarding potential benefits of supporting early, rather than delayed, peanut introduction during the period of complementary food introduction in infants.
Early childhood wheezers: identifying asthma in later life
Abstract
The airway microbiome in patients with severe asthma: Associations with disease features and severity
J Allergy Clin Immunol. 2015 Jul 25. pii: S0091-6749(15)00838-6. doi: 10.1016/j.jaci.2015.05.044. [Epub ahead of print]
Abstract
BACKGROUND:
OBJECTIVE:
Subscribe to:
Posts (Atom)